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INTRODUCTION
Fasudil (1-(5-isoquinolinesulphonyl)-homopiperazine) is
a newly developed drug which improves intracranial
ischemia as a result of the dilating effect of vasospasm (1,
2). The neuroprotective property of fasudil is due to its
effect that inhibits the activities of various protein kinases
including myosin light chain kinase, cyclic AMP-dependent
protein kinase, cyclic GMP-dependent protein kinase and
protein kinase C (3, 4).
Previous studies have shown that H-7, a protein kinase
inhibitor, inhibits the activation of transcription of human
immunodeficiency virus type1 (HIV-1) long terminal repeat
(5) and HIV-1 replication in chronically infected cell lines
(6). These effects of H-7 are caused by blockage of the
protein kinase C-dependent cascade (5, 6). The similar
efficacy of H-7 and fasudil as kinase inhibitors led to an
idea that fasudil inhibits HIV-1 replication. If so, fasudil
would be a candidate as a new anti-HIV-1 agent whose
mechanism is different from that of currently available
anti-HIV-1 drugs targeted for viral reverse transcriptase
(RT) and protease. To address this issue, we examined the
potential suppressive effect of fasudil on the replication of
HIV-1 in vitro .
MATERIALS AND METHODS
Cells
A human cervical cell line, HeLa, was maintained in
Dulbecco's modified Eagle's medium supplemented with
10% heat-inactivated fetal calf serum. CD4-positive human
lymphocytic cell lines, CEMx174, Jurkat, M8166, andMT-4,
were maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum. Human peripheral
blood mononuclear cells (PBMCs) were prepared and
used as previously described (7).
Cell proliferation assay
Cell proliferation was evaluated by the modified MTT
method designated WST-1 as indicated in the manufacture's
instruction (Dojindo Laboratories, Kumamoto, Japan).
Transfection and infection
For transfection, uncleaved plasmid DNA designated
pNL432 (an infectious molecular clone of HIV-1) (8) was
introduced into HeLa cells by the calcium-phosphate
coprecipitation method (8). CD4-positive cell lines and
PBMCs were infected with cell-free virus samples prepared
from transfected HeLa cells as previously described (9).
RT assay
Virion-associated RT activity was measured as described
previously (10).
RESULTS
Cytotoxicity of fasudil for T cell lines and PBMCs
As a first step to monitor the effectiveness of fasudil
(Asahi Chemical Industry Co., Ltd., Shizuoka, Japan)
against HIV-1, its cytotoxicity for various cell types was
evaluated (Fig.1). In a human CD4+ leukemia cell line,
Jurkat, obvious cytotoxic effects were observed when
fasudil was added to the culture at concentrations higher
than 100µM, and no cytotoxicity was detected at ̃37.5 µM
of fasudil (Fig.1 A). Similar results were obtained in the
other human T cell lines, CEMx174, M8166, and MT-4
(data not shown). In phytohemagglutinin P (PHA-P) (Difco
Laboratories, Detroit, USA.)-stimulated PBMCs, the cytotoxic
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dose of fasudil was basically similar to that in
Jurkat cells. In activated PBMCs cultivated
for 24 hours in complete medium (RPMI-1640
medium with 10% fetal calf serum, L-glutamine,
2-mercaptoethanol and antibiotics) (CM) (Fig.1
B) and for 15 days in CM supplemented with
50U/ml human recombinant interleukin-2 (rIL-2)
(Serotec Ltd., Oxford, England) (Fig.1 C), the
cytotoxic effect was seen at concentrations
higher than 100 µM of fasudil.
Effect of fasudil on HIV-1 replication in T cell
lines and PBMCs
On the basis of the cytotoxic data of fasudil
described above, concentrations below 50 µM
were used for the inhibition assay of virus
replication.
First, the effect of fasudil on HIV-1 replication
in T cell lines was monitored. As shown in
Fig.2, in the two cell lines (CEMx174 and
M8166), the virus growth kinetics in the
presence (5 µM) or absence of fasudil were surprisingly
similar. In a repeated experiment, essentially similar
results were obtained (data not shown). Furthermore,
cultivation of the two cell lines infected with various doses
of virus in the presence of higher concentration of fasudil
(50 µM) gave no significant effects with respect to virus
production at 14 days post-infection (data not shown).
We then asked whether fasudil is effective against HIV-1
growth in PBMCs, the natural target cells. Fig.3 shows
the replication kinetics of HIV-1 in PHA-P-stimulated
PBMCs cultivated in rIL-2-supplemented CM in the
presence of various concentrations of fasudil. On the peak
day of RT production, the activity was reduced by 75%,
50%, 34%, and 33% of that of a control (no fasudil) at
concentrations of 40, 20, 10, and 5 µM of fasudil, respec-
tively. In a repeated experiment, essentially similar results
were obtained (data not shown).
DISCUSSION
Our results here showed that fasudil has a suppressive
effect on HIV-1 growth in activated PBMCs but not in
established T cell lines. The basis for this observation is
unclear. It has been shown that cell activation is required
for HIV-1 replication in primary T lymphocytes (11, 12).
Fasudil could inhibit the activity of protein kinase(s)
required for HIV-1 replication in PBMCs but not in T cell
lines. It is possible that fasudil affects the function of the
nef gene which is known to be important for the viral
replication in PBMCs (13, 14) and disease progression
(15-17). A recent finding that fasudil inhibits Nef-dependent
cytotoxicity (18) may be related to its suppressive effect of
HIV-1 replication reported here.
Apart from the mechanism for the inhibitory effect, our
results show that fasudil has a potential as a candidate
for an anti-HIV-1 agent which can be administrated in
Fig.1. Cytotoxicity of fasudil for human lymphocytic cells. Jurkat cells (A) and unstimulated PBMCs (B) were cultured in CM in the presence
of fasudil for 48 and 24 hours, respectively, and cell proliferation was evaluated by the WST-1 method. (C) PBMCs activated with PHA-P (1 µg/
ml) were cultured in CM with 50 U/ml of rIL-2 and fasudil for 15 days (half volume of the medium was changed every 3 days), and the cell
growth was measured as above. Triplicate samples were analyzed (absorbance at 450 nm), and the averages with error bars are shown.
Fig.2. Effect of fasudil on HIV-1 replication in established cell lines. Cell-free
viruses (3 x 10５ RT units) obtained from HeLa cells transfected with pNL432 were
inoculated into 2 x106 cells of CEMx174 (A) and M8166 (B), and RT production
in the culture supernatants was monitored at indicated intervals. Symbols : ○,
mock-infection ; ●, virus growth in the absence of fasudil ; △, virus growth in the
presence of 5 µM of fasudil.
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combination with inhibitors of the viral RT or protease. To
further explore the possibility of fasudil as an anti-HIV-1
drug, animal experiments using simian immunodeficiency
virus/macaque model system are to be done.
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